Provided by Tiger Trade Technology Pte. Ltd.

TuHURA Biosciences, Inc.

0.8271
+0.00851.04%
Volume:180.21K
Turnover:150.53K
Market Cap:50.22M
PE:-1.25
High:0.8701
Open:0.8211
Low:0.8200
Close:0.8186
52wk High:5.50
52wk Low:0.7970
Shares:60.72M
Float Shares:54.29M
Volume Ratio:1.03
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6627
EPS(LYR):-1.2136
ROE:-418.06%
ROA:-60.16%
PB:3.04
PE(LYR):-0.68

Loading ...

Company Profile

Company Name:
TuHURA Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
1995
Employees:
19
Office Location:
10500 University Center Drive,Suite 110,Tampa,Florida,United States
Zip Code:
33612
Fax:
- -
Introduction:
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Directors

Name
Position
James Bianco
Chief Executive Officer and Director
James Manuso
Director and Chairman of the Board
Alan List
Director
Craig Tendler
Director
George Ng
Director
Robert E. Hoffman
Director

Shareholders

Name
Position
James Bianco
Chief Executive Officer and Director
Dan Dearborn
Chief Financial Officer